All Categories
From Testing to Treatment: Implementing Genomics and AI Tools...
Elisabeth Heath discusses genomic and AI-based biomarker tools in prostate cancer. Dr. Heath describes ArteraAI as a useful a [...]
Artera Presents Multiple ASCO 2026 Abstracts on Multimodal AI...
Validation of MMAI in node-positive HR+ breast cancer to determine chemotherapy benefit Concordance analysis between MMAI and [...]
External Validation of a Post-RP Multimodal AI Prognostic Model
Prognostication after radical prostatectomy (RP) remains one of the most clinically demanding challenges in prostate cancer m [...]
Multimodal Artificial Intelligence Prediction of Abiraterone Efficacy in Two...
<p>Long-term androgen deprivation therapy (LT-ADT) with radiotherapy is standard-of-care for high-risk localized prosta [...]
Artera Expands Its Validated Multimodal AI Platform to Metastatic...
First digital pathology-based test to provide individual risk estimates to help inform treatment planning in mHSPC SAN FRANCI [...]
High-Tech Healthcare in NJ – Medical treatments advance as...
New Jersey hospitals have long been on the cutting edge of medical technology in areas ranging from cancer treatments and car [...]
Tempus and Artera Collaborate to Expand Access to New...
Tempus and Artera Collaborate to Expand Access to New Prognostic Test for Prostate Cancer
Artificial Intelligence in Oncology: Clinical Applications, Challenges, and Opportunities
Artificial intelligence (AI) is reshaping cancer research and clinical oncology by enabling large-scale analysis of complex b [...]